Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Sacituzumab govitecan + trastuzumab is an investigational combination regimen consisting of the TROP2-directed antibody-drug conjugate (ADC) sacituzumab govitecan and the HER2-targeted monoclonal antibody trastuzumab. Sacituzumab govitecan delivers the topoisomerase I inhibitor payload SN-38 to TROP2-expressing tumor cells, while trastuzumab binds to HER2 to inhibit tumor cell proliferation and mediate antibody-dependent cellular cytotoxicity (ADCC). The combination has been evaluated in the phase II SATEEN trial (NCT06100874) for the treatment of patients with heavily pretreated HER2-positive metastatic breast cancer who progressed on trastuzumab deruxtecan (T-DXd). However, the trial failed to meet its primary endpoint of objective response rate (ORR), demonstrating limited clinical activity and significant hematologic toxicity.
- Other names
- SG + HSG + trastuzumabTrodelvy + HerceptinTrodelvy + Herceptin Hylectasacituzumab govitecan + trastuzumab and hyaluronidase-oysksacituzumab govitecan-hziy + trastuzumabsacituzumab govitecan-hziy + trastuzumab and hyaluronidase-oysk
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab govitecan + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + trastuzumab.